Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09

Eisen T et al. – The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported. This study showed that treatment with lenalidomide (25 mg/d) has a manageable safety profile in patients with previously treated metastatic malignant melanoma but no benefit in tumor response, time to progression, or overall survival in these patients.

Methods

Compared treatment with lenalidomide (25 mg/d on Days 1-21 of a 28-day cycle) to placebo in 306 patients with metastatic malignant melanoma
Treatment was continued until progression of disease or unacceptable toxicity

Results

No significant differences between lenalidomide and placebo in overall survival (median 5.9 months vs 7.4 months, respectively, time to progression (median 3.0 months vs 2.1 months), or Response Evaluation Criteria in Solid Tumors tumor response (5.3% vs 5.8%)
None of patients given placebo discontinued treatment because of treatment-related adverse events, compared with 4.6% of those treated with lenalidomide
Treatment-related myelosuppression observed in 2.0% of patients treated with placebo and 7.3% of patients treated with lenalidomide

<< Previous
Association of molecular markers with toxicity outcomes in a...

Next >>
Health-related quality of life in long-term survivors of...